| Identification | Back Directory | [Name]
SKI 178 | [CAS]
1259484-97-3 | [Synonyms]
SKI 178
N'-(1-(3,4-Dimethoxyphenyl)ethylidene)-3-(4-methoxyphenyl)-1H-pyrazole-5-carbohydrazide
resistant,SphK,cytotoxic,myeloid,Inhibitor,Apoptosis,leukemia,multi-drug,inhibit,SKI-178,cancer,Sphingosine kinase,SKI178,drug,sensitive,cell,SKI 178 | [Molecular Formula]
C21H22N4O4 | [MOL File]
1259484-97-3.mol | [Molecular Weight]
394.42 |
| Chemical Properties | Back Directory | [density ]
1.24±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 25 mg/ml; DMSO: 25 mg/ml; DMSO:PBS(pH 7.2) (1:4): 0.2 mg/ml | [form ]
A crystalline solid | [pka]
9.25±0.46(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
SKI 178 is a sphingosine kinase 1 specific small-molecule inhibitor. | [in vivo]
SKI-178 (20 mg/kg; retro-orbital injection under isoflurane anesthesia) inhibits leukemic progression in the MLL-AF9 model[3]. | Animal Model: | MLL-AF9 mouse model (leukemic mice)[3] | | Dosage: | 20 mg/kg | | Administration: | Retro-orbital injection under isoflurane anesthesia; three times per week for 1 and 3 weeks | | Result: | White blood cell (WBC) counts decreased from their initial 104 cells/μL levels and continued to decline after 3 weeks of treatment until they reached normal levels (~4×103 cells/μL).
|
| [IC 50]
SphK1; SphK2 | [storage]
Store at -20°C |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
|